|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
|
10570745 |
1999 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results show a common mechanism of CD30 overexpression in ALCL and HL, although the outcome of CD30 signaling differs between NPM-ALK-positive ALCL and NPM-ALK-negative ALCL, cutaneous ALCL, and HL as we recently reported.
|
16140928 |
2005 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
|
29390984 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab.
|
28708333 |
2017 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans.
|
28993768 |
2017 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.
|
28805662 |
2017 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cells expressed the HD-associated surface antigens CD30 and CD15 as well as the transferrin receptor (CD71).
|
8605360 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic immunophenotypic differences were found between CD30+ DLCL and HD.
|
8639911 |
1996 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These studies also have clarified the relationship of ALCL to Hodgkin's disease, another lymphoid malignancy associated with CD30 expression.
|
11266530 |
2001 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ten months following the diagnosis of Hodgkin's disease (HD), a 46-year-old woman presented cutaneous and leukemic involvement by CD30+ anaplastic large cells, from which a continuously growing, exogenous growth factor-independent T cell line was established.
|
8035614 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 sustain their cytotoxic function and cytokine secretion in vitro, and produce enhanced tumor control when infused intravenously in mice engrafted with human HL.
|
19377047 |
2009 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is suggested that the high-level nuclear Bcl-3 sequesters the (p50)(2) homodimer to the nucleus, which may account for the contradictory effect of CD30 stimulation on ALCL and HD.
|
12456498 |
2003 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although CD30 is not a specific RS cell marker, its characterization has assumed an important role not only in the differential diagnosis of HD, but also in the identification of a morphologically and clinically distinct type of large cell lymphoma, now designated as anaplastic large cell lymphoma (ALCL) (2).
|
10080826 |
1999 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma of T-cell type: clonal association with a CD30+ cutaneous lymphoma.
|
11727269 |
2001 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is a member of the tumor necrosis factor (TNF) receptor superfamily that is expressed on activated lymphocytes, as well as on neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).
|
11110706 |
2000 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Systemic anaplastic large cell lymphomas (sALCLs) comprise a heterogeneous group of relatively rare T-cell non-Hodgkin lymphomas that are characterized by CD30 expression.
|
28556361 |
2017 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In tumor cells, CD30 expression is most commonly associated with lymphoid malignancies (Hodgkin and non-Hodgkin lymphomas) and is a therapeutic target using anti-CD30 antibody.
|
28521633 |
2017 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's disease (HD) represents a phenotypically and genotypically heterogeneous lymphoma of CD30-positive tumour cells.
|
8946602 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 2011, the ADC brentuximab-vedotin, consisting of the CD30-specific chimeric mAb cAC10 and the potent tubulin toxin monomethyl auristatin E, gained regulatory approval as a well tolerated and highly active drug in patients with refractory and relapsed HL and ALCL.
|
24043362 |
2014 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas.
|
30841880 |
2019 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reporter gene assays revealed that the CD30 promoter (-413 to 84) induces a 50- to 1000-fold higher luciferase expression in CD30(+) human lymphoid cell lines (Co, Jurkat, and the Hodgkin's lymphoma-derived cell line L540) than in CD30(-) human lymphoid cell lines (DG75, SUP-T1, and U698M), CD30(-) human carcinoma cell lines (HeLa and MCF-7), or COS1 cells.
|
11004694 |
2000 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clonality detection rates in cHL improved as CD30-positive Reed-Sternberg (RS) cell density increased and CD20-positive B cell density decreased, although these correlations did not reach statistical significance.
|
22296097 |
2012 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context.234 CD30+ HL patients were enrolled.
|
29207679 |
2017 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL.
|
31616638 |
2019 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, CD40L induced a 40% to 60% reduction of the expression of the HD-associated CD30 antigen, another member of the TNF receptor superfamily.
|
7522624 |
1994 |